Sugi Predict

Sugi Predict / Compounds / SCHEMBL1655083

SCHEMBL1655083

SCHEMBL1655083

C[C@@H]1CN(c2ccc(Nc3ncc4ccn(-c5cc(F)c(CN6CCOCC6)c(F)c5)c4n3)cn2)C[C@H](C)N1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RPS6KA3 P51812 2/20 0.49
▸ STAT6 P42226 5/20 0.44
▸ JAK2 O60674 9/20 0.42
▸ BRD4 O60885 9/20 0.42
▸ FGFR1 P11362 1/20 0.40
▸ FGFR2 P21802 1/20 0.40
▸ FGFR4 P22455 1/20 0.40
▸ FGFR3 P22607 1/20 0.40
▸ IGF1R P08069 1/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ BRD2 P25440 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ BRD3 Q15059 1/20 0.39
▸ BRDT Q58F21 1/20 0.39
▸ AURKA O14965 2/20 0.39
▸ CDK4 P11802 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1655086 1.00 RPS6KA3 (0.49) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL29439968 0.92 RPS6KA3 (0.53) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL31061211 0.92 RPS6KA3 (0.53) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL22511944 0.92 JAK2 (0.46) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL1654793 0.90 AURKA (0.42) RPS6KA3JAK2BRD4FGFR1FGFR2
SCHEMBL1654803 0.90 RPS6KA3 (0.43) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL1654986 0.90 RPS6KA3 (0.40) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL1654988 0.90 RPS6KA3 (0.40) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL4288402 0.88 RPS6KA3 (0.47) RPS6KA3STAT6JAK2BRD4FGFR1
SCHEMBL4288398 0.88 RPS6KA3 (0.47) RPS6KA3STAT6JAK2BRD4FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 — — US claimed
JP-2011511034-A — — 2011-04-07 — — JP claimed
EP-2247591-A1 PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS Novartis AG (CH) 2010-11-10 — — EP claimed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US claimed
WO-2009098236-A1 PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS NOVARTIS AG (CH) 2009-08-13 — — WO claimed
US-11833215-B2 CKIT antibody drug conjugates NOVARTIS AG (CH) 2023-12-05 — — US disclosed
US-20200405875-A1 CKIT ANTIBODY DRUG CONJUGATES NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2020-12-31 — — US disclosed
WO-2020200291-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI) , INC. (CN) 2020-10-08 — — WO disclosed
US-10786578-B2 CKIT antibody drug conjugates NOVARTIS AG (CH) 2020-09-29 — — US disclosed
US-20200129632-A1 ANTIBODY DRUG CONJUGATES NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2020-04-30 — — US disclosed
US-10238748-B2 Anti-CDH6 antibody drug conjugates NOVARTIS AG (CH) 2019-03-26 — — US disclosed
US-20180193475-A1 CKIT ANTIBODY DRUG CONJUGATES MORPHOSYS AG (DE) 2018-07-12 — — US disclosed
EP-2531487-B1 ARYL BENZYLAMINE COMPOUNDS NOVARTIS AG (CH) 2014-06-18 — — EP disclosed
US-8420657-B2 Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors NOVARTIS AG (CH) 2013-04-16 — — US disclosed
EP-2531487-A1 ARYL BENZYLAMINE COMPOUNDS Novartis AG (CH) 2012-12-12 — — EP disclosed
WO-2011095452-A1 ARYL BENZYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-08-11 — — WO disclosed
US-20110190258-A1 ARYL BENZYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-08-04 — — US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US disclosed
US-20090203688-A1 HETEROCYCLIC COMPOUNDS NOVARTIS AG 2009-08-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200405875-A1 CKIT ANTIBODY DRUG CONJUGATES EPCAM, CD44, CKAP4 RPS6KA3 2894/4885STAT6 3969/4885JAK2 906/4885
US-20200129632-A1 ANTIBODY DRUG CONJUGATES EPCAM, CD44, ABL1 RPS6KA3 3090/4885STAT6 4258/4885JAK2 973/4885
US-10786578-B2 CKIT antibody drug conjugates EPCAM, CD44, CKAP4 RPS6KA3 2894/4885STAT6 3969/4885JAK2 906/4885
US-20180193475-A1 CKIT ANTIBODY DRUG CONJUGATES EPCAM, CD44, CKAP4 RPS6KA3 2894/4885STAT6 3969/4885JAK2 906/4885
US-10238748-B2 Anti-CDH6 antibody drug conjugates EPCAM, CD44, CDH1 RPS6KA3 2776/4885STAT6 2837/4885JAK2 3693/4885
US-11833215-B2 CKIT antibody drug conjugates EPCAM, CD44, CKAP4 RPS6KA3 2894/4885STAT6 3969/4885JAK2 906/4885
US-20110190258-A1 ARYL BENZYLAMINE COMPOUNDS UGT2B7, NAT1, CYP2B6 RPS6KA3 1438/4885STAT6 3816/4885JAK2 240/4885
US-20090203688-A1 HETEROCYCLIC COMPOUNDS ABL1, JAK2, JAK1 RPS6KA3 303/4885STAT6 601/4885JAK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.